Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity

Smith, Levi M.; Strittmatter, Stephen M.

doi:10.1101/cshperspect.a024075

Cited by 109

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity

Smith, Levi M., Strittmatter, Stephen M.·2017·Cold Spring Harbor Perspectives in Medicine

DOI 10.1101/cshperspect.a024075PMC PMC5411685

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/cshperspect.a024075

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The human relevance of synaptic Aβ binding partners identified in cell culture systems and mouse models is still debated.
“Synaptic Aβ binding partners have been identified in cell culture systems and mouse models, but their human relevance is still debated (reviewed in [5, 30, 46, 63]).”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [63]
Synaptic Aβ binding partners have been identified in cell culture systems and mouse models.
“Synaptic Aβ binding partners have been identified in cell culture systems and mouse models, but their human relevance is still debated (reviewed in [5, 30, 46, 63]).”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [63]
The study of synaptic binding partners of Aβ yielded many candidates.
“The study of synaptic binding partners of Aβ yielded many candidates—reviewed in [30, 46, 63].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [63]
Most binding partners have not been studied in human brain nor using human derived Aβ species.
“It is relevant to note that most binding partners have not been studied in human brain nor using human derived Aβ species [38, 63].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [63]
Amyloid-β oligomers bind to a protein complex comprised of cellular prion protein (PrPc) along with other proteins including leukocyte immunoglobulin-like receptor subfamily B2/paired immunoglobulin-like type 2 receptor B (LilrB2), and possibly also Nogo-66 receptor 1 (Nogo-1), low-affinity nerve growth factor (NGF) receptor, and the metabotropic glutamate receptor 5.
“Amyloid-β oligomers bind to a protein complex comprised of cellular prion protein (PrPc) along with other proteins including leukocyte immunoglobulin-like receptor subfamily B2/paired immunoglobulin-like type 2 receptor B (LilrB2), and possibly also Nogo-66 receptor 1 (Nogo-1), low-affinity nerve growth factor (NGF) receptor [125] (Figure 3), and the metabotropic glutamate receptor 5 [126].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [125]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
Retracted
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Self-citation
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
Sortilin is essential for proNGF-induced neuronal cell death
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004) · Nature · doi:10.1038/nature02319 · Cited by 962
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587
Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Self-citation
Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911829107 · Cited by 466
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model
Cissé, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D. B., Sun, B., Orr, A., Lotz, G., Kim, D. H., Hamto, P., et al. (2011) · Nature · doi:10.1038/nature09635 · Cited by 433
PirB restricts ocular-dominance plasticity in visual cortex
Syken, J., GrandPre, T., Kanold, P. O., & Shatz, C. J. (2006) · Science · doi:10.1126/science.1128232 · Cited by 340
Upregulation of Surface α4β2 Nicotinic Receptors Is Initiated by Receptor Desensitization after Chronic Exposure to Nicotine
Fenster, C. P., Whitworth, T. L., Sheffield, E. B., Quick, M. W., & Lester, R. A. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-04804.1999 · Cited by 204
Epidermal growth factor receptor is a preferred target for treating Amyloid-β–induced memory loss
Wang, L., Chiang, H.-C., Wu, W., Liang, B., Xie, Z., Yao, X., Ma, W., Du, S., & Zhong, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208011109 · Cited by 190
Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits
Izzo, N. J., Staniszewski, A., To, L., Fa, M., Teich, A. F., Saeed, F., Wostein, H., Walko, T., Vaswani, A., Wardius, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111898 · Cited by 180
Molecular Dissection of the Interaction between Amyloid Precursor Protein and Its Neuronal Trafficking Receptor SorLA/LR11
Andersen, O. M., Schmidt, V., Spoelgen, R., Gliemann, J., Behlke, J., Galatis, D., McKinstry, W. J., Parker, M. W., Masters, C. L., Hyman, B. T., et al. (2006) · Biochemistry · doi:10.1021/bi052120v · Cited by 178
Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models
Kostylev, M. A., Kaufman, A. C., Nygaard, H. B., Patel, P., Haas, L. T., Gunther, E. C., Vortmeyer, A., & Strittmatter, S. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.643577 · Cited by 133
Self-citation
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer’s disease
Kam, T.-I., Song, S., Gwon, Y., Park, H., Yan, J.-J., Im, I., Choi, J.-W., Choi, T.-Y., Kim, J., Song, D.-K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66827 · Cited by 128
Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity
Nicoll, A. J., Panico, S., Freir, D. B., Wright, D., Terry, C., Risse, E., Herron, C. E., O’Malley, T., Wadsworth, J. D. F., Farrow, M. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3416 · Cited by 119
The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain
Carlo, A.-S., Gustafsen, C., Mastrobuoni, G., Nielsen, M. S., Burgert, T., Hartl, D., Rohe, M., Nykjaer, A., Herz, J., Heeren, J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2425-12.2013 · Cited by 117
Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease Aβ Synaptotoxicity
Klyubin, I., Nicoll, A. J., Khalili-Shirazi, A., Farmer, M., Canning, S., Mably, A., Linehan, J., Brown, A., Wakeling, M., Brandner, S., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3526-13.2014 · Cited by 74

Flagged first, then by citations

Research works printed but not linked: 85

10.1073/pnas.0503689102 · DOI · Paper page
10.1126/science.1161151 · DOI
10.1523/JNEUROSCI.6500-10.2011 · DOI · Paper page
10.1074/jbc.M111.248724 · DOI
10.1126/scitranslmed.3010157 · DOI
10.1016/S1074-7613(00)00027-3 · DOI
10.1083/jcb.200610139 · DOI · Paper page
10.1097/00004647-200109000-00001 · DOI
10.1038/35000219 · DOI
10.1186/1471-2202-11-130 · DOI · Paper page
10.1523/JNEUROSCI.1459-11.2011 · DOI
10.1038/nn1372 · DOI
10.1146/annurev.pharmtox.37.1.205 · DOI
10.1172/JCI58642 · DOI · Paper page
2001, β-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer’s disease, J Neurosci, 21, 4125, 10.1523/JNEUROSCI.21-12-04125.2001 · DOI · Paper page
10.1093/brain/awt375 · DOI
10.1074/jbc.M112.423954 · DOI
10.1038/35053072 · DOI
10.1038/383166a0 · DOI
10.1038/ncomms1341 · DOI
2006, Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism, Nat Neurosci, 10, 67
10.1073/pnas.1405803111 · DOI · Paper page
10.1212/WNL.0000000000000364 · DOI
10.1523/JNEUROSCI.0395-10.2010 · DOI · Paper page
10.1038/35000226 · DOI
Hogg R , Raggenbass M , Bertrand D . 2003. Nicotinic acetylcholine receptors: from structure to brain function. In Reviews of physiology, biochemistry and pharmacology, pp. 1–46. Springer, New York. · DOI
10.1038/ng.803 · DOI · Paper page
10.1074/jbc.270.43.25752 · DOI · Paper page
10.1016/j.neuron.2010.09.034 · DOI · Paper page
10.1038/ncomms4374 · DOI
10.1074/jbc.M110.208108 · DOI
10.1074/jbc.M004175200 · DOI · Paper page
10.1006/exnr.1999.7196 · DOI
10.1371/journal.pone.0111899 · DOI · Paper page
10.1074/jbc.M100857200 · DOI · Paper page
10.1016/S0952-7915(02)00400-4 · DOI
10.1126/science.1242077 · DOI · Paper page
10.1016/S0166-2236(00)01749-5 · DOI · Paper page
10.1093/hmg/ddr542 · DOI
10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.0.CO;2-T · DOI
10.1038/ng.2802 · DOI · Paper page
10.1523/JNEUROSCI.3359-12.2012 · DOI
10.1523/JNEUROSCI.1858-12.2012 · DOI
10.1016/j.neuron.2009.05.012 · DOI · Paper page
1997, Cytotoxic amyloid peptides inhibit cellular 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis, J Neurochem, 69, 2285, 10.1046/j.1471-4159.1997.69062285.x · DOI
2003, Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations, J Neurosci, 23, 10879, 10.1523/JNEUROSCI.23-34-10879.2003 · DOI · Paper page
10.1016/S0002-9440(10)65184-X · DOI · Paper page
1983, Effects of chronic nicotine infusion on tolerance development and nicotinic receptors, J Pharmacol Exp Ther, 226, 817, 10.1016/S0022-3565(25)21831-6 · DOI · Paper page
10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M · DOI
10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8 · DOI
10.1002/ana.410380413 · DOI · Paper page
10.1073/pnas.89.2.569 · DOI
10.1128/MCB.01072-06 · DOI
1992, Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins, J Biol Chem, 267, 14998, 10.1016/S0021-9258(18)42138-2 · DOI
10.1523/JNEUROSCI.4946-05.2006 · DOI · Paper page
10.1038/onc.2010.356 · DOI
10.1523/JNEUROSCI.3214-13.2013 · DOI
10.1523/JNEUROSCI.3291-05.2006 · DOI
10.1523/JNEUROSCI.4504-06.2006 · DOI
10.1038/35000287 · DOI
10.1046/j.1365-2567.2003.01592.x · DOI
10.1093/nar/gkt1114 · DOI
10.1073/pnas.91.22.10703 · DOI
10.1038/emboj.2011.86 · DOI
10.1523/JNEUROSCI.2746-07.2007 · DOI
10.1074/jbc.M710574200 · DOI · Paper page
10.1074/jbc.M112.400358 · DOI
10.1001/archneur.61.8.1200 · DOI · Paper page
1992, Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface, J Biol Chem, 267, 14987, 10.1016/S0021-9258(18)42137-0 · DOI
10.3233/JAD-2009-1096 · DOI
10.1523/JNEUROSCI.3882-05.2006 · DOI · Paper page
10.1212/01.WNL.0000046581.81650.D0 · DOI
10.1038/379346a0 · DOI
10.1038/nn.3178 · DOI
2009, RAGE does not affect amyloid pathology in transgenic ArcAβ mice, Neurodegener Dis, 6, 270, 10.1159/000261723 · DOI · Paper page
10.1038/416535a · DOI · Paper page
10.1371/journal.pone.0095995 · DOI
10.1046/j.1471-4159.2000.0751155.x · DOI
10.1242/jcs.125393 · DOI · Paper page
10.1016/0306-4522(89)90360-6 · DOI
10.1186/gb-2009-10-11-r130 · DOI
10.1093/nar/gks1114 · DOI
2002, Alzheimer’s amyloid peptides compete for insulin binding to the insulin receptor, J Neurosci, 22, 1
10.1172/JCI119772 · DOI
10.1248/bpb.28.1342 · DOI

Sorted by citations

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
Lizama, B. N., Kahle, J., Catalano, S. M., Caggiano, A. O., Grundman, M., & Hamby, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076251 · Cited by 54
Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials
Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I. S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104823 · Cited by 48
Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial
Sheline, Y. I., Snider, B. J., Beer, J. C., Seok, D., Fagan, A. M., Suckow, R. F., Lee, J.-M., Waligorska, T., Korecka, M., Aselcioglu, I., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010725 · Cited by 45
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Colom-Cadena, M., Toombs, J., Simzer, E., Holt, K., McGeachan, R., Tulloch, J., Jackson, R. J., Catterson, J. H., Spires-Jones, M. P., Rose, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02679-6 · Cited by 44
Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease
Marcatti, M., Fracassi, A., Montalbano, M., Natarajan, C., Krishnan, B., Kayed, R., & Taglialatela, G. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04255-9 · Cited by 38

Authors: Smith, L. M., & Strittmatter, S. M.
ORCID: Strittmatter, Stephen M.
Venue: Cold Spring Harbor Perspectives in Medicine
Publisher: Cold Spring Harbor Laboratory
Published: 2016-12-09
Volume: 7
Issue: 5
Pages: a024075
ISSN: 2157-1422
DOI: 10.1101/cshperspect.a024075
PMC: PMC5411685
Cited by: 109
References: 28
Language: en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks